MorphoSys begins dosing patients in Phase 2 lymphoma drug study

MOR208’s efficacy in patients with relapsed or refractory NHL will be assessed in the open-label, multicentre trial.

MorphoSys chief development officer Dr. Arndt Schottelius said MOR208 cancer program is highly potential.

"Evaluating MOR208 in NHL and B-ALL – building on the data we already have for CLL – should enable us to assess the therapeutic benefit and broader commercial potential of the molecule in haematological malignancies," Schottelius added.

"Broadening the drug’s development program into additional indications is intended to maximize the value of this compound."

Secondary outcome measures of the single-arm clinical trial include response duration, safety and pharmacokinetics of MOR208.

The trial will enrol around120 patients in four separate sub-indications (FL, MCL, DLBCL and other forms of indolent NHL).

At present, the compound is being evaluated even in a phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL).